Pharmaceutical emulsion compositions comprising progestogen
Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.
1. A sterile, ready-to-use, pharmaceutical oil-in water emulsion composition for parenteral administration comprising:
0.015 to 1.2% wt/vol progestogen;
0.5-30% wt/vol oil wherein the oil comprises at least 85% wt/wt triglyceride based on the total oil content of the emulsion;
0.0425-12.5% wt/vol phospholipid;
61.4-99.4% wt/vol aqueous medium;
wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1% wt/wt of the oil.
2. The composition according to claim 1 , wherein the progestogen is present in an amount greater than or equal to 2.2% wt/wt of the oil.
3. The composition according to claim 1 , wherein the composition contains less than 2.5% wt/vol benzyl benzoate.
4. The composition according to claim 1 , wherein the phospholipid is present in an amount within the range of 8.4-42.5% wt/wt of the oil.
5. The composition according to claim 1 , wherein the progestogen is present in an amount greater than 2.5% wt/wt of the oil.
6. The composition according to claim 1 , wherein said composition contains 0.005-10 wt % of a co-surfactant.
7. The composition according to claim 6 , wherein the co-surfactant is selected from oleate, oleic acid and combinations thereof, and is present in the range of 0.005-2.5 wt %.
8. The composition according to claim 1 , wherein the progestogen is progesterone.
9. The composition according to claim 1 , wherein the composition contains an osmotic agent.
10. The composition according to claim 9 , wherein the osmotic agent comprises glycerol.
11. The composition according to claim 1 , wherein the composition is suitable for intravenous administration.
12. The composition according claim 1 , wherein the composition has an osmolality of between 200 and 1000 mOsm/kg.
13. The compositions according to claim 1 , wherein the composition has a PFAT 5 value of ≦0.05%.
14. The composition according to claim 1 , wherein the emulsion comprises a dispersed oil phase with droplet particles having a volume-based mean diameter of ≦300 nm.
15. The composition according to claim 14 , wherein the droplet particles of the dispersed oil phase have a volume-based mean diameter of ≦250 nm.
16. A method of treatment, comprising administering a composition of claim 1 to a subject in need thereof.
17. The method of claim 16 , wherein said subject is human.
18. The method of claim 16 , wherein said subject suffers from a traumatic central nervous system injury.
19. A method of manufacturing a composition according to claim 1 , comprising:
(a) combining water, phospholipid and, optionally, an osmotic agent, to produce an aqueous composition;
(b) combining progestogen and oil to produce an oily composition; and
(c) combining the aqueous composition and the oily composition, followed by homogenization to form a homogenous oil-in-water emulsion.
20. The method of claim 19 , wherein step (c) comprises adding the oily composition to the aqueous composition, and homogenization at greater than or equal to 350 bar.